BioScrip (NASDAQ:BIOS) Lowered to “Hold” at BidaskClub

BidaskClub downgraded shares of BioScrip (NASDAQ:BIOS) from a buy rating to a hold rating in a research note issued to investors on Saturday morning, BidAskClub reports.

Several other analysts have also recently commented on the company. ValuEngine upgraded BioScrip from a sell rating to a hold rating in a report on Wednesday, October 2nd. Canaccord Genuity lifted their price target on BioScrip from $3.50 to $4.00 and gave the company a buy rating in a report on Thursday, August 8th. Finally, SunTrust Banks lifted their price target on BioScrip from $3.25 to $4.25 and gave the company a buy rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $4.63.

Shares of NASDAQ BIOS traded down $0.07 during trading on Friday, hitting $3.59. 894,600 shares of the company were exchanged, compared to its average volume of 1,109,970. The company has a market cap of $484.43 million, a price-to-earnings ratio of -7.33 and a beta of 0.49. The firm’s fifty day moving average price is $3.46 and its 200 day moving average price is $2.81. BioScrip has a 1 year low of $1.56 and a 1 year high of $4.14.

Several large investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of BioScrip during the 3rd quarter worth about $63,000. North Star Investment Management Corp. purchased a new stake in shares of BioScrip during the 3rd quarter worth about $64,000. White Pine Capital LLC purchased a new stake in shares of BioScrip during the 2nd quarter worth about $475,000. Venor Capital Management LP grew its holdings in shares of BioScrip by 3.4% during the 2nd quarter. Venor Capital Management LP now owns 12,333,605 shares of the company’s stock worth $32,067,000 after purchasing an additional 400,000 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of BioScrip during the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 77.46% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Further Reading: What does a bar chart display?

Analyst Recommendations for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.